CQS Cayman’s Vertex Pharmaceuticals VRTX Stock Holding History

CQS Cayman’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-20,000	Closed	-$2.08M	–	179
2015 Q3	$2.08M	Buy	+20,000	New	+$2.57M	0.17%	89

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CQS Cayman's VRTX Position: Q4 2015 in Review

CQS Cayman sold out of Vertex Pharmaceuticals (VRTX) in Q4 2015, closing a stake of 20,000 shares — an estimated $2.08M sold.

CQS Cayman first reported a position in VRTX in Q3 2015 and held it in 1 quarter. The position peaked at $2.08M in Q3 2015. 517 funds tracked by Wall St. Rank hold VRTX as of Q4 2015.

CQS Cayman reported no remaining Vertex Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
CQS Cayman sold 20,000 Vertex Pharmaceuticals shares in Q4 2015, an estimated $2.08M.
CQS Cayman first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 1 quarter.
CQS Cayman's Vertex Pharmaceuticals position peaked at $2.08M in Q3 2015.
517 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2015.

Based on CQS Cayman's 13F filing for Q4 2015, filed 11 Feb 2016.